News and Announcements
Unhedged short-listed as finalist for Finnies 2022
- Published May 26, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
FinTech Australia has announced their Finnies 2022 Finalists, and we’re invited! Unhedged is a finalist in two categories: Emerging FinTech Organisation of the Year and Excellence in Wealth Management.
Here are the descriptions for each award category:
Emerging FinTech Organisation of the Year
This award recognises a fintech organisation that is delivering transformative new financial services offerings through the innovative use of technology to its customers.
Excellence in Wealth Management (including PFM and Robo)
This award recognises the fintech providing the most innovative, cost-effective and high-quality investment and wealth management solution, either direct to consumer or to the financial advice and wealth management industry. This can also include asset management solutions.
We’re grateful (and proud) to be considered for these awards as part of the sixth annual edition of FinTech Australia’s fintech business awards. And we really love all those award category adjectives!
So, do you feel like making a transformative investment today? Check out our app!
About The Company
Unhedged is a super simple app-based experience that allows everyday investors to assign their money to advanced AI trading algorithms to access algorithmic performance. The algorithms are built on known factors and enhanced by our quant team to made suitable to trade retail funds.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
